|Day Low/High||20.06 / 20.92|
|52 Wk Low/High||16.63 / 31.75|
An investor should make good money on any turn in the drug maker's business or in investor sentiment.
The market is off its worst levels of the day. Big biotech and biopharma are providing strength today, with Biogen , Gilead Sciences and Mylan all sporting solid gains in a down market. Energy has made a bit of a comeback, but still is down nearly 2...
"Papa's in the swing. He ain't too hip about that new breed babe. He ain't no drag. Papa's got a brand new bag." -- James Brown, Papa's Got a Brand New Bag Jim "El Capitan" Cramer clearly outlined the key risks facing Valeant Pharmaceuticals (VRX) t...
Solid earnings and the start of some M&A activity may be just what this sector needs to rise.
It would take a rally and close back above $46 to alter the current bearish cast to the charts.
I noted in my previous missive that my ursine friend Jim Chanos spoke out on CNBC's Fast Money Halftime show today in favor of shorting the Chinese stock market. Well, he also just expressed skepticism on Valeant Pharmaceuticals (VRX) -- another vie...
"Valeant, of course, was a sewer ... [and its directors deserve] all the opprobrium they are getting." -- Charlie Munger, vice chairman of Berkshire Hathaway (BRK.A, BRK.B), at this weekend's annual Berkshire shareholder meeting Pershing Square's Bi...
Valeant delighted shareholders Monday with news that Perrigo's Joseph Papa is getting into the driver's seat.
Other companies have suffered following the debacle.
Valuations of some small-cap concerns, such as Relypsa, are ridiculously cheap.
David Einhorn is a man of many talents, including playing poker -- and watching where he stacks his chips investment-wise is a worthwhile endeavor, too.
With biotech stocks getting smashed on the stock market and big pharma getting hammered on the presidential campaign trail, generic drug stocks look awfully appealing.
The market looks like it is expecting a significant domestic contraction in 2016, but I don't see it.
The year has not started the way most pundits and prognosticators had envisioned.
Mylan and Endo International look like bargains at current prices.
History indicates pharmaceutical companies with low multiples offer payoffs down the road.
Look for 2015's record run of mergers and acquisitions to continue.
CAT not going down on bearish news gets us closer to a bottom and buy recommendation.
Stocks are trading in a relatively narrow range, but are slightly down after Federal Reserve chair Janet Yellen hinted at a possible December rate hike. Still, her remarks are only having a minor impact on the market given the many Fed "head fakes" ...
There's very little movement on Wall Street right now as the European bourses close. Equities are slightly down across the board, as are gold and oil -- but nothing's moving much today. The volatility we saw in August and September seems to have fad...
Good morning! Bret Jensen here. I'm happy to be filling in for Doug Kass during this last trading day of October. It's been a good month for investors after a very bumpy August and September. All the major indices are up nicely for the month, despit...
Make incremental moves until the onslaught in the space is over.
Meanwhile, make incremental moves until the onslaught in the space is over.
Mylan (MYL) gained ground Tuesday after it announced plans to start a $27.1 billion hostile takeover of Perrigo (PRGO).